The estimated Net Worth of James S Burns is at least $1.68 Milion dollars as of 26 March 2019. Mr. Burns owns over 34,848 units of Vermillion stock worth over $1,588,220 and over the last 17 years he sold VRML stock worth over $0. In addition, he makes $92,000 as Independent Director at Vermillion.
Sign up
Mr. Burns VRML stock SEC Form 4 insiders trading
James has made over 3 trades of the Vermillion stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 34,848 units of VRML stock worth $139,392 on 26 March 2019.
The largest trade he's ever made was buying 34,848 units of Vermillion stock on 26 March 2019 worth over $139,392. On average, James trades about 3,464 units every 87 days since 2007. As of 26 March 2019 he still owns at least 397,055 units of Vermillion stock.
You can see the complete history of Mr. Burns stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Burns biography
James S. Burns is the Independent Director of Vermillion Inc. has been our director since June 2005 and served as Chairman of the Board from September 2011 to March 2013. He is the Chair of our Nominating and Governance Committee and a member of our Compensation Committee. Dr. Burns served as Chairman of the Board and Executive Chairman, from 2014 to 2016, and currently serves as Executive Chairman and President of Phenomics Health, Inc., a privately held company. He also served as President and Chief Executive Officer, from 2009 to 2014, of Assurex Health, Inc., an informatics-based precision medicine company focused on treatment decision support products for patients with neuropsychiatric disorders. Prior to joining Assurex Health, Dr. Burns was the President and Chief Executive Officer of EntreMed, Inc. from June 2004 to December 2008, and a director from September 2004 to December 2008. Dr. Burns was a co-founder and, from 2001 to 2003, served as President and as Executive Vice President of MedPointe Pharmaceuticals, a specialty pharmaceutical company that develops, markets and sells branded prescription pharmaceuticals. From 2000 to 2001, Dr. Burns served as a founder and Managing Director of MedPointe Capital Partners, a private equity firm that led a leveraged buyout to form MedPointe Pharmaceuticals. Previously, Dr. Burns was a founder, Chairman, President and Chief Executive Officer of Osiris Therapeutics, Inc., a biotech company developing therapeutic stem cell products for the regeneration of damaged or diseased tissue. Dr. Burns has also been Vice Chairman of HealthCare Investment Corporation and a founding General Partner of Healthcare Ventures L.P., a venture capital partnership specializing in forming companies building around new pharmaceutical and biotechnology products; Group President at Becton, Dickinson and Company, a multidivisional biomedical products company; and Vice President and Partner at Booz & Company, Inc., a multinational consulting firm.
What is the salary of James Burns?
As the Independent Director of Vermillion, the total compensation of James Burns at Vermillion is $92,000. There are 6 executives at Vermillion getting paid more, with Valerie Palmieri having the highest compensation of $941,832.
How old is James Burns?
James Burns is 73, he's been the Independent Director of Vermillion since 2013. There are no older and 6 younger executives at Vermillion.
What's James Burns's mailing address?
James's mailing address filed with the SEC is C/O VERMILLION, INC., 12117 BEE CAVES RD, BLDG 3 STE 100, AUSTIN, TX, 78738.
Insiders trading at Vermillion
Over the last 17 years, insiders at Vermillion have traded over $1,008,376 worth of Vermillion stock and bought 29,557,130 units worth $34,088,488 . The most active insiders traders include Jack W Schuler, Henri George Schuler oraz Larry Noracle Partners Lp F.... On average, Vermillion executives and independent directors trade stock every 59 days with the average trade being worth of $1,572,028. The most recent stock trade was executed by Robert Harry Beechey on 15 November 2019, trading 5,000 units of VRML stock currently worth $3,550.
What does Vermillion do?
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.
What does Vermillion's logo look like?
Complete history of Mr. Burns stock trades at Vermillion
Vermillion executives and stock owners
Vermillion executives and other stock owners filed with the SEC include:
-
Valerie Palmieri,
President, Chief Executive Officer, Director -
Robert Beechey,
Chief Financial Officer -
Nancy Cocozza,
Independent Director -
James LaFrance,
Independent Chairman of the Board -
Veronica Jordan,
Independent Director -
David Schreiber,
Independent Director -
James Burns,
Independent Director -
Sandra Brooks,
Independent Director -
Jack W Schuler,
-
Peter S Roddy,
Director -
Carl Severinghaus,
Director -
Larry Noracle Partners Lp O...,
-
Donald G Munroe,
SVP Business Development & CSO -
Henri George Schuler,
10% owner -
Holly B Bauzon,
VP Managed Markets -
Fred Ferrara,
Chief Information Officer -
Rajen Dalal,
Director -
Gail S Page,
President and CEO -
Qun Zhou,
Interim CFO -
Laura Ann Miller,
SVP Sales & Cust Experience -
Robert St Leger Goggin,
Director -
Ashish Kohli,
VP of Corporate Strategy -
Michael J Callaghan,
Director -
Marian E Sacco,
See Remarks -
Thomas H Mclain,
CEO & President -
James L Rathmann,
Director -
Eric Varma,
Director -
Larry Noracle Partners Lp O...,
-
John F Hamilton,
Director -
William C Wallen,
Director -
Bruce A Huebner,
Director -
William B. Creech,
VP Sales and Marketing -
Eric Schoen,
VP Finance & CAO -
Eric T Fung,
VP-Chief Science Officer -
Sandra A. Gardiner,
VP & Chief Financial Officer -
Judy Bruner,
Director -
Partners L Pwiggins James P...,
-
Diagnostics Inc Quest,
10% owner -
Kenneth J Conway,
Director -
Simon C. Shorter,
VP, Corp Business Development -
John A Young,
Director -
Larry Noracle Partners Lp F...,